In vitro activity of oritavancin (LY333328), vancomycin, clindamycin, and metronidazole against Clostridium perfringens, Propionibacterium acnes, and anaerobic Gram-positive cocci

被引:19
作者
Citron, DM
Kwok, YY
Appleman, MD
机构
[1] Univ So Calif, Los Angeles Cty Med Ctr, Microbial Res Lab, Los Angeles, CA 90033 USA
[2] Univ So Calif, Keck Sch Med, Los Angeles, CA 90089 USA
关键词
oritavancin; vancomycin; anaerobes; susceptibility;
D O I
10.1016/j.anaerobe.2004.10.005
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Using an agar dilution method, we determined the in vitro activity of oritavancin, vancomycin, clindamycin and metronidazole against 114 unique clinical isolates of Gram-positive anaerobes. MIC(90)s ( mu g/mL) for oritavancin were as follows: Clostridium perfringens 1.0, Propionibacterium acnes 0.25, Peptostreptococcus anaerobius 0.25, Peptoniphilus asaccharolyticus 0.5, Finegoldia magna 0.25, Micromonas. micros 0.25, and Anaerococcus prevotii 0.25. On a weight basis, oritavancin is slightly more active than vancomycin against the strains tested. The oritavancin MICs are comparable to those previously reported against staphylococci and enterococci. Oritavancin shows excellent potential for treatment of infections containing Gram-positive anaerobes such as these. (c) 2004 Elsevier Ltd. All rights reserved.
引用
收藏
页码:93 / 95
页数:3
相关论文
共 8 条
  • [1] Mechanism of action of oritavancin and related glycopeptide antibiotics
    Allen, NE
    Nicas, TI
    [J]. FEMS MICROBIOLOGY REVIEWS, 2003, 26 (05) : 511 - 532
  • [2] Activity of a new glycopeptide antibiotic (LY333328) against enterococci and other resistant Gram-positive organisms
    Fraise, AP
    Andrews, J
    Wise, R
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 40 (03) : 423 - 425
  • [3] Evaluation of the in-vitro activity of the glycopeptide antibiotic LY333328 in comparison with vancomycin and teicoplanin
    Harland, S
    Tebbs, SE
    Elliott, TSJ
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1998, 41 (02) : 273 - 276
  • [4] In vitro activity and spectrum of LY333328, a novel glycopeptide derivative
    Jones, RN
    Barret, MS
    Erwin, ME
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (02) : 488 - 493
  • [5] Jousimies-Somer H, 2002, WADSWORTH KTL ANAERO
  • [6] *NCCLS, 2003, 7UUA6 NCCLS
  • [7] In vitro activity of LY333328 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus, and penicillin-resistant Streptococcus pneumoniae
    Patel, R
    Rouse, MS
    Piper, KE
    Cockerill, FR
    Steckelberg, JM
    [J]. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1998, 30 (02) : 89 - 92
  • [8] In vitro activity of LY 333328 against anaerobic Gram-positive bacteria
    Sillerström, E
    Wahlund, E
    Nord, CE
    [J]. JOURNAL OF CHEMOTHERAPY, 1999, 11 (02) : 90 - 92